X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ribociclib (141) 141
palbociclib (108) 108
breast cancer (82) 82
oncology (80) 80
index medicus (79) 79
abemaciclib (78) 78
humans (48) 48
combination (43) 43
cdk4 (38) 38
cyclin-dependent kinase 4 - antagonists & inhibitors (36) 36
cyclin-dependent kinase 6 - antagonists & inhibitors (34) 34
endocrine therapy (34) 34
letrozole (34) 34
therapy (34) 34
female (33) 33
metastasis (33) 33
breast neoplasms - drug therapy (32) 32
fulvestrant (31) 31
cdk4/6 inhibitors (28) 28
pharmacology & pharmacy (28) 28
phase-i (28) 28
cancer (27) 27
cyclin-dependent kinases (27) 27
cell cycle (25) 25
care and treatment (24) 24
medicine & public health (24) 24
analysis (22) 22
cdk4/6 inhibitor (22) 22
pd 0332991 (22) 22
cell-cycle (20) 20
clinical trials (20) 20
cyclin-dependent kinase 4 (19) 19
advanced breast cancer (18) 18
dependent kinase 4/6 (17) 17
metastatic breast cancer (17) 17
protein kinase inhibitors - therapeutic use (17) 17
1st-line treatment (16) 16
breast neoplasms - pathology (16) 16
breast-cancer (16) 16
cdk4/6 (16) 16
double-blind (16) 16
erbb-2 protein (16) 16
lee011 (16) 16
tumors (16) 16
antitumor-activity (15) 15
metastases (15) 15
obstetrics & gynecology (15) 15
6 inhibitor (14) 14
6 inhibitors (14) 14
chemotherapy (14) 14
cyclin-dependent kinase (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
epidermal growth factor (13) 13
patients (13) 13
postmenopausal women (13) 13
protein kinase inhibitors - pharmacology (13) 13
review (13) 13
article (12) 12
health aspects (12) 12
neoplasms. tumors. oncology. including cancer and carcinogens (12) 12
aminopyridines - therapeutic use (11) 11
animals (11) 11
cancer therapies (11) 11
kinases (11) 11
phase-ii (11) 11
aminopyridines - administration & dosage (10) 10
antimitotic agents (10) 10
antineoplastic agents (10) 10
cdk4/6 inhibition (10) 10
cdk6 (10) 10
cyclin-dependent kinase 4 - metabolism (10) 10
cyclin-dependent kinase 6 - metabolism (10) 10
hormone receptor-positive (10) 10
kinase 4/6 inhibitor (10) 10
purines - administration & dosage (10) 10
purines - therapeutic use (10) 10
receptor, erbb-2 - metabolism (10) 10
safety (10) 10
toxicity (10) 10
women (10) 10
aminopyridines - pharmacology (9) 9
breast neoplasms - metabolism (9) 9
drug therapy (9) 9
endocrine resistance (9) 9
hormones (9) 9
medical colleges (9) 9
piperazines - pharmacology (9) 9
piperazines - therapeutic use (9) 9
purines - pharmacology (9) 9
pyridines - pharmacology (9) 9
pyridines - therapeutic use (9) 9
solid tumors (9) 9
trial (9) 9
antineoplastic agents - administration & dosage (8) 8
antineoplastic agents - adverse effects (8) 8
antineoplastic agents - pharmacology (8) 8
antineoplastic agents - therapeutic use (8) 8
cell biology (8) 8
cyclin d (8) 8
expression (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 07/2018, Volume 29, Issue 7, pp. 1541 - 1547
Abstract Background The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for... 
Advanced breast cancer | Ribociclib | CDK4/6 inhibitor | PALBOCICLIB | THERAPY | ONCOLOGY | advanced breast cancer | ribociclib
Journal Article
Медицинский совет, ISSN 2079-701X, 06/2019, Issue 10, pp. 72 - 80
Breast cancer steadily holds leading market positions in the malignancy morbidity and mortality pattern. The treatment of metastatic breast cancer remains an... 
endocrinotherapy | breast cancer | ribociclib
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2018, Volume 167, Issue 3, pp. 607 - 614
Journal Article
Oncotarget, ISSN 1949-2553, 10/2019, Volume 10, Issue 59
Journal Article
American Journal of Health-System Pharmacy, ISSN 1079-2082, 08/2019, Volume 76, Issue 16, pp. 1183 - 1202
PURPOSE.The pharmacology, clinical activity, safety, and place in therapy of the cyclin-dependent kinase (CDK) inhibitors palbociclib, ribociclib, and... 
COST-EFFECTIVENESS ANALYSIS | 1ST-LINE TREATMENT | abemaciclib | breast cancer | PHASE-II | COMBINATION | ESTROGEN-RECEPTOR | RIBOCICLIB | palbociclib ribociclib | PALBOCICLIB PLUS LETROZOLE | THERAPY | FULVESTRANT | PHARMACOLOGY & PHARMACY | CDK inhibitors
Journal Article
Artificial Cells, Nanomedicine, and Biotechnology, ISSN 2169-1401, 12/2019, Volume 47, Issue 1, pp. 4001 - 4011
Triple-negative breast cancer (TNBC) stands for a refractory subtype, which predicts poor prognosis and has no effective therapies yet for improving it. Given... 
apoptosis | proliferation | cell cycle | ribociclib (LEE011) | Triple-negative breast cancer
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 81, pp. 35226 - 35240
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6... 
LEE011 | Ribociclib | Selectivity | Preclinical | CDK4/6 inhibitor
Journal Article
Breast, The, ISSN 0960-9776, 2016, Volume 28, pp. 191 - 198
Abstract Objectives Cyclin D–cyclin-dependent kinase (CDK) 4/6–inhibitor of CDK4/6–retinoblastoma (Rb) pathway hyperactivation is associated with hormone... 
Hematology, Oncology and Palliative Medicine | Ribociclib | Breast cancer | CDK4/6 | Letrozole | PLACEBO | ENDOCRINE THERAPY | PROLIFERATION | PROGNOSTIC VALUE | OBSTETRICS & GYNECOLOGY | PALBOCICLIB | CIRCULATING TUMOR-CELLS | ONCOLOGY | DNA | Breast Neoplasms - surgery | Cyclin D2 - genetics | Oncogene Proteins - genetics | Triazoles - administration & dosage | Triazoles - adverse effects | Gene Expression - drug effects | Cyclin-Dependent Kinase 4 - genetics | Humans | Middle Aged | Aminopyridines - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Purines - administration & dosage | Cyclin E - genetics | Nitriles - pharmacokinetics | Nitriles - administration & dosage | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | DNA, Neoplasm - blood | Cyclin D3 - genetics | Female | Neoadjuvant Therapy | Triazoles - pharmacokinetics | Purines - adverse effects | Aminopyridines - administration & dosage | Purines - pharmacokinetics | Cyclin-Dependent Kinase 6 - genetics | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Ki-67 Antigen - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Retinoblastoma Protein - genetics | Aged | Receptor, ErbB-2 - analysis | Nitriles - adverse effects | Antimitotic agents | Research | Antineoplastic agents | Oncology, Experimental | Cancer | Analysis
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 01/2018, Volume 27, Issue 1, pp. 8 - 11
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2016, Volume 6, Issue 4, pp. 353 - 367
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 12/2019, Volume 19, Issue 6, pp. 399 - 404
Signaling through the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway can mediate therapeutic resistance in HER2-positive breast cancer. Preclinical studies... 
Ribociclib | Continuous daily low-dose | Trastuzumab | CDK4/6 inhibitors | HER2-positive
Journal Article
BREAST CANCER RESEARCH AND TREATMENT, ISSN 0167-6806, 08/2018, Volume 170, Issue 3, pp. 535 - 545
Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative... 
Health-related quality of life | THERAPY | Advanced breast cancer | ONCOLOGY | SCORES | GUIDELINES | Ribociclib | Endocrine therapy | QLQ-C30 | EUROPEAN-ORGANIZATION | Hormone receptor-positive | CDK4/6 inhibitor
Journal Article
Journal of Chromatography B, ISSN 1570-0232, 07/2017, Volume 1057, pp. 110 - 117
LC–MS/MS methods to measure ribociclib in mouse plasma and Ringer’s solution were successfully developed and validated. Reverse phase chromatography was... 
Ribociclib | Solid phase extraction | Microdialysis | CDK4/6 | LC–MS/MS | Ringer’s solution | LC-MS | CDK4 | Solid Phase extraction
Journal Article
Current Treatment Options in Oncology, ISSN 1527-2729, 6/2019, Volume 20, Issue 6, pp. 1 - 13
Journal Article
Breast Care, ISSN 1661-3791, 07/2016, Volume 11, Issue 3, pp. 167 - 173
Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast... 
Review Article | Cyclin-dependent kinase | Ribociclib | Abemaciclib | Breast cancer | Palbociclib | CDK6 | RETINOBLASTOMA PROTEIN | ONCOLOGY | COMBINATION | OBSTETRICS & GYNECOLOGY | Review
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.